Vardenafil/Selected Protease Inhibitors Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Severe. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

Protease inhibitors may slow down how quickly your liver processes vardenafil. Vardenafil may speed up how quickly your liver processes your protease inhibitor.

What might happen:

The amount of vardenafil in your blood may increase and cause harmful effects. The amount of protease inhibitor in your blood may decrease and it may not work as well.

What you should do about this interaction:

Contact your healthcare professionals (e.g. doctor or pharmacist) right away about using these medicines together. If your are taking indinavir, do not take more than 2.5 mg of vardenafil every 24 hours. If you are taking lopinavir or ritonavir, do not take more than 2.5 mg of vardenafil every 72 hours.Get medical help right away if you experience a painful or prolonged erection. Let your doctor know if you experience fainting, dizziness, or changes in vision.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

  • 1.Levitra (vardenafil hydrochloride) Canadian prescribing information. Bayer, Inc. October 24, 2006.
  • 2.Levitra (vardenafil hydrochloride trihydrate) UK summary of product characteristics. Bayer plc December 20, 2006.
  • 3.Levitra (vardenafil hydrochloride) US prescribing information. Bayer Pharmaceuticals Corporation September, 2015.
  • 4.Crixivan (indinavir sulfate) US prescribing information. Merck & Co., Inc. September, 2016.
  • 5.Kaletra (lopinavir/ritonavir tablets) US prescribing information. Abbott Laboratories December, 2019.
  • 6.Norvir (ritonavir) US prescribing information. Abbott Laboratories December, 2019.
  • 7.Aptivus (tipranavir) US prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc. June, 2018.
  • 8.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.